National notificable conditions (historical) CDC. (2025) Accessed August 12, 2025, https://ndc.services.cdc.gov/search-results-year/

Price M, Ballard C, Benedetti J et al. (2024 Oct 6) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021. Neuro Oncol 26(Supplement_6):vi1–vi85. https://doi.org/10.1093/neuonc/noae145

Siegel DA, Li J, Henley SJ et al. (2018 Jun 29) Geographic variation in pediatric cancer incidence - United States, 2003-2014. MMWR Morb Mortal Wkly Rep 67(25):707–713. https://doi.org/10.15585/mmwr.mm6725a2

Ballard CAP, Wang Y, Kruchko C, Barnholtz-Sloan JS, Li Y, Ostrom QT (2025 Aug) Characteristics of long-term glioblastoma survivors diagnosed from 2010 to 2016 in the United States. Cancer Epidemiol 97:102810. https://doi.org/10.1016/j.canep.2025.102810

Petkov VI, Byun JS, Ward KC, et al. (2024 Aug 1) Reporting tumor genomic test results to SEER registries via linkages. J Natl Cancer Inst Monogr 2024(65):168–179. https://doi.org/10.1093/jncimonographs/lgae013

Reiner AS, Mishra Meza A, Panageas KS, Moss NS (2025 Apr) Provider volume impacts neurosurgical procedure selection in older patients with high-grade glioma. Cancer Med 14(8):e70866. https://doi.org/10.1002/cam4.70866

Friedman S, Negoita S (2024 Aug 1) History of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst Monogr 2024(65):105–109. https://doi.org/10.1093/jncimonographs/lgae033

Article  PubMed  PubMed Central  Google Scholar 

Lupo PJ, Siegel DA, Schussler NC et al. (2025 Jun 14) Enrollment in children’s oncology group’s clinical trials: population-based linkage with the national childhood cancer registry. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaf134

Article  PubMed  Google Scholar 

Hill SM, Michels FS, Knight K et al. (2023 Fall) Harnessing the Power of Cancer registries to advance our understanding of pediatric Cancer. J Registry Manag 50(3):80–81

PubMed  PubMed Central  Google Scholar 

Li XR, Kruchko C, Wu XC et al. (2016 Winter) Are benign and borderline brain tumors underreported? J Registry Manag 43(4):187–194

PubMed  CAS  Google Scholar 

Huang B, Luo A, Durbin EB et al. (2017 May) Incidence of CNS tumors in Appalachian children. J Neurooncol 132(3):507–512. https://doi.org/10.1007/s11060-017-2403-2

Article  PubMed  PubMed Central  Google Scholar 

Sarfraz Z, Jayram D, Ozair A et al. (2025 May 23) Association of health disparities with Glioblastoma treatment and outcomes: insights from a 15-year national cohort (2005-2020). Brain Sci 15(6). https://doi.org/10.3390/brainsci15060556

Horowitz MA, Brown NJ, Gendreau J et al. (2025 Jul) The association of hospital volume status with treatment and survival outcomes of intracranial meningioma patients: a multivariable analysis of the national cancer database. J Neurooncol 173(3):731–738. https://doi.org/10.1007/s11060-025-05011-2

Article  PubMed  Google Scholar 

Dmukauskas M, Cioffi G, Waite KA et al. (2024 Aug 28) Sex difference in disease-related adverse events post-diagnosis of lung cancer brain metastases in Medicare individuals ≥ 66 years of age. Cancers (basel) 16(17). https://doi.org/10.3390/cancers16172986

Dmukauskas M, Cioffi G, Waite KA et al. (2024 May) Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment. J Neurooncol 168(1):111–123. https://doi.org/10.1007/s11060-024-04652-z

Article  PubMed  PubMed Central  Google Scholar 

Johnson KJ, Brown DS, Thompson T, Barnes JM, King AA (2025 Apr) Associations between central nervous system tumor diagnosis stage and survival and Medicaid enrollment among children, adolescents, and young adults. Neurooncol Pract 12(2):246–256. https://doi.org/10.1093/nop/npae094

IQVIA IQVIA research and Devlopment solutions: discover the future of clincial ressearch. https://www.iqvia.com/solutions/research-and-development

Price M, Low JT, Chavez G et al. (2025 Jul 22) Improvements in survival for glioblastoma in the post-Stupp protocol era. Neuro Oncol., https://doi.org/10.1093/neuonc/noaf134

Schwartz NRM, DeBusk K, Forero-Torres A et al. (2021) Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer. Future Oncol. 2021/09/01, 17(26):3457–3463. https://doi.org/10.2217/fon-2020-1292

Mitrofan LM, Krukas-Hampel MR, Mendoza LA (2018) Clinical characteristics of 3, 030 glioblastoma multiforme (GBM) patients in high, upper middle and lower middle economic regions based on real-world data (RWD). Ann Oncol 29: viii126). https://doi.org/10.1093/annonc/mdy273.372

Merative The most trusted real-world data and anlytics for health research. https://www.merative.com/real-world-evidence/real-world-data-analytics#skiptheform-marketscan

Ray S, Bonafede MM, Mohile NA (2014 May) Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits 7(3):140–149

Mukherjee D, Patil CG, Todnem N et al. (2013 Jan) Racial disparities in Medicaid patients after brain tumor surgery. J Clin Neurosci 20(1):57–61. https://doi.org/10.1016/j.jocn.2012.05.014

Burudpakdee C, Wong W, Seetasith A, Corvino FA, Yeh W, Gubens M (2018 May) Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer 119:103–111. https://doi.org/10.1016/j.lungcan.2018.03.008

Flatiron Generate real-world evidence from over 4 million patient journeys with industry-leading real-world data. https://flatiron.com/real-world-evidence/real-world-data

Cioffi G, Ascha MS, Waite KA et al. (2024 May 3) Sex differences in odds of brain metastasis and outcomes by brain metastasis status after advanced melanoma diagnosis. Cancers (basel) 16(9). https://doi.org/10.3390/cancers16091771

Sabari JK, Yu HA, Mahadevia PJ et al. (2025 Sep) Overall survival in EGFR-Mutant advanced NSCLC treated with first-line osimertinib: a cohort study integrating clinical and Biomarker Data in the United States. J Thorac Oncol 20(9):1268–1278. https://doi.org/10.1016/j.jtho.2025.04.010

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK (2019 Jun) Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecol Oncol 153(3):568–573. https://doi.org/10.1016/j.ygyno.2019.03.004

Sciences CL Caris CODEai - real world Clinico-genomic platform

Cioffi G, Waite KADmukauskas M et al. (2024 Jan-Dec) Sex differences in glioblastoma response to treatment: impact of MGMT methylation. Neurooncol Adv 6(1):vdae031. https://doi.org/10.1093/noajnl/vdae031

Johnson M, Bell ALauing KL et al. (2023 Dec 1) Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence. Clin Cancer Res 29(23):4973–4989. https://doi.org/10.1158/1078-0432.Ccr-23-0834

T Datasets and analytics - access fit-for-purpose real-world datasets and solutions. https://trinetx.com/data-sets-analytics/?_gl=1*me6n3m*_up*MQ.*_ga*ODMzMDcwMDg1LjE3NTUxMDQ1NjI.*_ga_ND9FN4NT6M*czE3NTUxMDQ1NjEkbzEkZzAkdDE3NTUxMDQ1NjEkajYwJGwwJGgw

Shenoy G, Slagle-Webb BKhunsriraksakul C et al. (2024 Jan 29) Analysis of anemia and iron supplementation among glioblastoma patients reveals sex-biased association between anemia and survival. Sci Rep 14(1):2389. https://doi.org/10.1038/s41598-024-52492-8

Xiao T, Kumar PLobbous M et al. (2025 Sep 2) Depot medroxyprogesterone acetate and risk of Meningioma in the US. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2025.3011

Bhanja D, Zhu JWilding H et al. (2025 Aug 1) A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy. Clin Cancer Res 31(15):3276–3284. https://doi.org/10.1158/1078-0432.Ccr-24-2681

Baggett CD, Jackson BEGreen L et al. (2024 Sep 2) Cancer information and population health resource: a resource for catchment area data and cancer outcomes research. JNCI Cancer Spectr 8(5). https://doi.org/10.1093/jncics/pkae069

Singh S, Molina E, Perraillon M, Fischer SM (2023 Aug) Post-acute care outcomes of cancer patients <65 reveal disparities in care near the end of life. J Palliat Med 26(8):1081–1089. https://doi.org/10.1089/jpm.2022.0190

Perraillon MC, Liang R, Sabik LM, Lindrooth RC, Bradley CJ (2022 Jun) The role of all-payer claims databases to expand central cancer registries: experience from Colorado. Health Serv Res 57(3):703–711. https://doi.org/10.1111/1475-6773.13901

Optum (2025) Understand costs and utilization with tried-and-true data. https://business.optum.com/en/data-analytics/life-sciences/real-world-data/claims-data.html?selectedTab=Data%20to%20meet%20your%20needs

Ostrom QT, Lu D, Lu R, Baker MC (2022 Oct 3) Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma. Neuro Oncol 24(10):1807–1809. https://doi.org/10.1093/neuonc/noac145

Dadey DYA, Rodrigues A, Haider G, Pollom EL, Adler JR, Veeravagu A (2022 Jul) Impact of socio-economic factors on radiation treatment after resection of metastatic brain tumors: trends from a private insurance database. J Neurooncol 158(3):445–451. https://doi.org/10.1007/s11060-022-04031-6

McLarney M, Fergestrom N, Zheng J, Pezzin LE (2024 May) Rehabilitation after brain tumor resection: a national study of postacute care service use through insurance claims data. Pm R 16(5):441–448. https://doi.org/10.1002/pmrj.13117

White MC, Babcock FHayes NS et al. (2017, 123 Suppl Dec 15) The history and use of cancer registry data by public health cancer control programs in the United States. Cancer 24(Suppl 24):4969–4976. https://doi.org/10.1002/cncr.30905

Louis DN, Perry AReifenberger G et al. (2016 Jun) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

WHO classification of tumours of the central nervous system. Int Agency For Res on Cancer (2016)

Waite KA, Cioffi GKruchko C et al. (2022 Aug) Aligning the central brain tumor registry of the United States (CBTRUS) histology groupings with current definitions. Neurooncol Pract 9(4):317–327. https://doi.org/10.1093/nop/npac025

Organization WH (1978) International classification of diseases: [9th] ninth revision, basic tabulation list with alphabetic index. Int Classif of Dis: [9th] Ninth Revision, Basic Tabulation List With Alphabetic Index

Jack A, Percy C, Sobin L, Whelan S (2000) International classification of diseases for oncology: ICD-O. World Health Organ

National cancer Act of 1971, 92nd congress § 1828 (1971)

Cancer registries amendment Act, 102nd cong (1992). § 515

Benign brain tumor cancer registries amendment act, 107th cong [§ 260] (2002)

International Agency for Research on Cancer (2024) Cancer incidence in five continents. Cancer Incidence In Five Continents. Int Agency For Res on Cancer XII

Engholm G, Ferlay JChristensen N et al. (2010 Jun) NORDCAN-a Nordic tool for cancer information, planning, quality control and research. Acta Oncologica (Stockholm, Sweden)., 49(5):725–736. https://doi.org/10.3109/02841861003782017

Soerjomataram I, Cabasag CBardot A et al. (2023 Jan) Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. The Lancet Oncol 24(1):22–32. https://doi.org/10.1016/s1470-2045(22)00704-5

Williamson C, Williamson S, Jiang R, Sudmeier L, Esiashvili N, Eaton BR (2024) The impact of radiation therapy variables on pediatric high-grade glioma outcomes: a national cancer database analysis. Pediatr Blood Cancer 71(1):e30751. https://doi.org/10.1002/pbc.30751

Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer AM (2022 May) An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin 72(3):287–300. https://doi.org/10.3322/caac.21714

Schneeweiss S, Avorn J (2005 Apr) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337. https://doi.org/10.1016/j.jclinepi.2004.10.012

Funk MJ, Landi SN (2014 Dec) Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr Epidemiol Rep 1(4):175–185. https://doi.org/10.1007/s40471-014-0027-z

Khozin S, Miksad RA, Adami J et al. (2019 Nov 15) Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer 125(22):4019–4032. https://doi.org/10.1002/cncr.32383

Kabadi SM, Near A, Wada K, Burudpakdee C (2019 Dec) Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med 8(17):7174–7185. https://doi.org/10.1002/cam4.2559

Ramsey SD, Onar-Thomas A, Wheeler SB (2024 Mar 20) Real-world database studies in oncology: a call for standards. J Clin Oncol 42(9):977–980. https://doi.org/10.1200/jco.23.02399

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK (2019) Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. Gynecologic Oncol 153(3):568–573. https://doi.org/10.1016/j.ygyno.2019.03.004

Cote DJ, Smith-Warner SACreed JH et al. (2021 Apr) Circulating lipids and glioma risk: results from the UK biobank. Nurses’ Health Study, And Health Professionals Follow-Up Study. Cancer Causes Control 32(4):347–355. https://doi.org/10.1007/s10552-021-01391-8

Matthews AA, Danaei G, Islam N, Kurth T (2022) Target trial emulation: applying principles of randomised trials to observational studies. BMJ 378:e071108. https://doi.org/10.1136/bmj-2022-071108

Topff L, Petrychenko LJain N et al. (2025 Jun) A data-centric approach to deep learning for brain metastasis analysis at MRI. Radiology 315(3):e242416. https://doi.org/10.1148/radiol.242416